Lewy Body Dementia Treatment Market Report 2026

Lewy Body Dementia Treatment Market Overview

• Lewy Body Dementia Treatment market size has reached to $4.69 billion in 2025 • Expected to grow to $6.51 billion in 2030 at a compound annual growth rate (CAGR) of 6.7% • Growth Driver: Surging Brain Disorder Prevalence Fuels Lewy Body Dementia Treatment Market • Market Trend: Innovative Medicine In Lewy Body Dementia Treatment Market • North America was the largest region in 2025.

What Is Covered Under Lewy Body Dementia Treatment Market?

Lewy body dementia treatment refers to medications and nonmedical therapies, such as physical, occupational, and speech therapies, to manage symptoms as much as possible. The treatment is used for the healing and control of some of the symptoms and to reduce hallucinations, confusion, drowsiness, movement problems, and disturbed sleep. The main drug types in lewy body dementia treatment market are antidepressants, antipsychotic drugs, benzodiazepine, carbidopa-levodopa, cholinesterase inhibitors, and modafinil. Antidepressants refer to medications that are prescribed to treat depression. It is used to treat anxiety disorders, obsessive-compulsive disorder (OCD), chronic pain, eating disorders, and post-traumatic stress disorder (PTSD). They work by increasing the levels of certain chemicals in the brain that help improve mood. The distribution channel includes hospitals pharmacies, retail pharmacies, online pharmacies, and others, that are used for Alzheimer's disease, dementia, and Parkinson's disease.

What Is The Lewy Body Dementia Treatment Market Growth Forecast?

The lewy body dementia treatment market size is expected to see strong growth in the next few years. It will grow to $6.51 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to rising demand for personalized treatment plans, expanding access to neurological care, increasing focus on quality of life improvement, growing availability of advanced drug formulations, higher investment in dementia treatment research. Major trends in the forecast period include increasing use of combination drug therapies, growing reliance on symptom-based treatment approaches, rising adoption of non-pharmacological therapies, expanding use of cholinesterase inhibitors, growing focus on sleep and behavioral symptom management.

Global Lewy Body Dementia Treatment Market Segmentation

1) By Drug Type: Antidepressants, Carbidopa-Levodopa, Cholinesterase Inhibitors 2) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels 3) By Application: Cognitive Symptom Management, Neuropsychiatric and Behavioral Symptom Management, Motor Symptom Management, Sleep and Wakefulness Disorder Management Subsegments: 1) By Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressants 2) By Carbidopa-Levodopa: Immediate-Release Formulations, Extended-Release Formulations 3) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

What Is The Driver Of The Lewy Body Dementia Treatment Market?

The rising prevalence of brain-related disorders is expected to propel the growth of the lewy body dementia treatment market going forward. Brain disorders refer to any disorder that impairs brain function. The impairment can be mild, moderate, or severe, depending on the extent of brain damage. Lewy body dementia treatment is used to treat brain disorders such as hallucinations, confusion, and drowsiness by increasing brain chemicals to improve alertness and cognition. For instance, in July 2024, according to the National Health Service, a UK-based government agency, there were 487,432 patients diagnosed with dementia (a progressive brain disorder affecting memory, thinking, and daily activities) by June 30, 2024. Therefore, the rising prevalence of brain-related disorders is driving the growth of the lewy body dementia treatment industry.

Key Players In The Global Lewy Body Dementia Treatment Market

Major companies operating in the lewy body dementia treatment market are Mallinckrodt Pharmaceuticals Co., BioArctic AB, Sumitomo Pharma Co. Ltd., Jazz Pharmaceuticals Inc., Allergan plc, Novartis International AG, Pfizer Inc., Bayer AG, Boehringer Ingelheim International GmbH., Merck & Co. Inc., Biogen Inc., Biohaven Pharmaceutical Holding Company Ltd., Bristol Myers Squibb Company, Calliditas Therapeutics AB, Chiesi USA Inc., GlaxoSmithKline plc, Eisai Co. Ltd., Bausch Health Companies Inc., Hisamitsu Pharmaceutical Co. Inc., Lundbeck Inc.

Global Lewy Body Dementia Treatment Market Trends and Insights

Major companies operating in the lewy body dementia treatment market are focusing on developing innovative treatments such as monoclonal antibody therapies that target underlying neurodegenerative mechanisms, to improve cognitive outcomes and slow disease progression compared with traditional symptomatic treatments that offer limited impact on disease pathology. Monoclonal antibodies help reduce toxic protein accumulation in the brain, thereby addressing key drivers of cognitive decline in dementia-related disorders. For instance, in January 2023, Biogen Inc., a US-based multinational biotechnology company, developed its new medicine, lecanemab, which is a humanized monoclonal antibody. This medicine is used to treat Alzheimer's disease, which is part of the disease in Lewy body dementia. The main unique benefit of lecanemab is that it reduces the levels of brain amyloid. It treats the brain and clears the amyloid plaques thought to cause cognitive impairment and dementia in Alzheimer's disease.

What Are Latest Mergers And Acquisitions In The Lewy Body Dementia Treatment Market?

In October 2024, Cognition Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, partnered with the University of Miami Miller School of Medicine to advance awareness and research efforts for Lewy body dementia (LBD), the second most common form of degenerative dementia. With this collaboration, Cognition Therapeutics Inc. and the University of Miami Miller School of Medicine aim to improve understanding of LBD, support early diagnosis, and accelerate therapeutic development, including initiatives related to CT1812, Cognition Therapeutics’ investigational synaptic-protective therapy. The University of Miami Miller School of Medicine is a US-based academic medical institution specializing in clinical research, medical education, and advanced patient care.

Regional Outlook

North America was the largest region in the Lewy body dementia treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Lewy Body Dementia Treatment Market?

The lewy body dementia treatment market consists of revenues earned by entities by providing speech and language therapy, physiotherapy, and psychological therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The lewy body dementia treatment market also includes sales of rivastigmine, donepezil, and galantamine products, which are used in providing lewy body dementia treatment services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Lewy Body Dementia Treatment Market Report 2026?

The lewy body dementia treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the lewy body dementia treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.